Overview

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

Status:
Enrolling by invitation
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Prospective phase 2a clinical trial to demonstrate proof-of-concept for simultaneous hyperpolarized [1-13C]pyruvate and 18F-FDG for positron emission tomography (PET) and MRS (magnetic resonance spectroscopy) in a PET/MR scanner in patients with cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Rigshospitalet, Denmark
Treatments:
Fluorodeoxyglucose F18